Edition:
India

INSYS Therapeutics Inc (INSYQ.PK)

INSYQ.PK on OTC Markets Group

0.08USD
15 Nov 2019
Change (% chg)

$-0.00 (-0.61%)
Prev Close
$0.08
Open
$0.08
Day's High
$0.12
Day's Low
$0.08
Volume
132,757
Avg. Vol
201,576
52-wk High
$7.39
52-wk Low
$0.03

Latest Key Developments (Source: Significant Developments)

Owens & Minor Announces New Organizational Structure
Wednesday, 6 Nov 2019 

Nov 6 (Reuters) - Owens & Minor Inc ::OWENS & MINOR ANNOUNCES NEW ORGANIZATIONAL STRUCTURE TO BETTER SERVE CUSTOMERS.OWENS & MINOR INC - MARK ZACUR NAMED TO POSITION OF CHIEF COMMERCIAL OFFICER;.OWENS & MINOR INC - JEFF JOCHIMS NAMED CHIEF OPERATING OFFICER; ANDY LONG TO JOIN AS CHIEF FINANCIAL OFFICER.OWENS & MINOR INC - ANDY LONG TO JOIN AS CHIEF FINANCIAL OFFICER, EFFECTIVE NOVEMBER 11.OWENS & MINOR INC - ANDY LONG TO JOIN AS CHIEF FINANCIAL OFFICER, EFFECTIVE NOVEMBER 11.OWENS & MINOR INC - LONG SUCCEEDS ROBERT SNEAD.OWENS & MINOR INC - LONG MOST RECENTLY SERVED AS CEO OF INSYS THERAPEUTICS.  Full Article

Insys Therapeutics Inc - Co, Units Filed Joint Chapter 11 Plan Liquidation Of Co And Its Affiliated Debtors
Wednesday, 18 Sep 2019 

Sept 17 (Reuters) - Insys Therapeutics Inc ::INSYS THERAPEUTICS INC - CO, UNITS FILED JOINT CHAPTER 11 PLAN LIQUIDATION OF CO AND ITS AFFILIATED DEBTORS, AND RELATED DISCLOSURE STATEMENT.  Full Article

Insys Therapeutics Inc Says Consummated Transactions Contemplated By Hikma Purchase Agreement
Friday, 30 Aug 2019 

Aug 29 (Reuters) - INSYS Therapeutics Inc ::INSYS THERAPEUTICS INC - CONSUMMATED TRANSACTIONS CONTEMPLATED BY HIKMA PURCHASE AGREEMENT.  Full Article

Delisting Of Securities Of Ftd Companies, Kaixin Auto Holdings (Warrant Only), Cytrx Corporation, And Insys Therapeutics From Nasdaq Stock Market
Saturday, 22 Jun 2019 

June 21 (Reuters) - CytRx Corp ::DELISTING OF SECURITIES OF FTD COMPANIES, KAIXIN AUTO HOLDINGS (WARRANT ONLY), CYTRX CORPORATION, AND INSYS THERAPEUTICS FROM NASDAQ STOCK MARKET.  Full Article

Insys Therapeutics Q3 Adjusted Loss Per Share $0.37
Tuesday, 6 Nov 2018 

Nov 5 (Reuters) - INSYS Therapeutics Inc ::INSYS THERAPEUTICS REPORTS THIRD QUARTER 2018 RESULTS.Q3 ADJUSTED LOSS PER SHARE $0.37.Q3 EARNINGS PER SHARE VIEW $-0.21 -- THOMSON REUTERS I/B/E/S.Q3 LOSS PER SHARE $0.41.Q3 REVENUE $18.3 MILLION VERSUS $30.7 MILLION.Q3 REVENUE VIEW $23.5 MILLION -- THOMSON REUTERS I/B/E/S.INSYS THERAPEUTICS - HAD $113.0 MILLION IN CASH, CASH EQUIVALENTS & SHORT-TERM & LONG-TERM INVESTMENTS WITH NO DEBT OUTSTANDING AS OF SEPT. 30, 2018.  Full Article

Insys Therapeutics To Assess Strategic Alternatives For Opioid-Related Assets
Tuesday, 6 Nov 2018 

Nov 5 (Reuters) - INSYS Therapeutics Inc ::INSYS THERAPEUTICS TO ASSESS STRATEGIC ALTERNATIVES FOR OPIOID-RELATED ASSETS.INSYS THERAPEUTICS INC - INSYS HAS ENGAGED JMP SECURITIES LLC AS ITS FINANCIAL ADVISOR TO ASSIST WITH PROCESS..INSYS THERAPEUTICS - COMMENCED A PROCESS TO REVIEW STRATEGIC ALTERNATIVES FOR ITS PORTFOLIO OF OPIOID-RELATED ASSETS.  Full Article

Insys Therapeutics Reports First Quarter 2018 Results
Wednesday, 9 May 2018 

May 8 (Reuters) - INSYS Therapeutics Inc ::INSYS THERAPEUTICS REPORTS FIRST QUARTER 2018 RESULTS.Q1 LOSS PER SHARE $0.28.Q1 REVENUE $38.5 MILLION VERSUS $51.8 MILLION.Q1 REVENUE VIEW $25.7 MILLION -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE VIEW $-0.18 -- THOMSON REUTERS I/B/E/S.Q1 ADJUSTED LOSS PER SHARE $0.19.NET REVENUE IN Q1 WAS $23.9 MILLION.  Full Article

Insys Says Working With Authorities To Resolve Issues Related To "Inappropriate Actions" Taken By Former Employees​
Monday, 19 Mar 2018 

March 19 (Reuters) - Insys Therapeutics Inc ::INSYS THERAPEUTICS REITERATES COMMITMENT TO COMPLIANT AND ETHICAL BUSINESS PRACTICES AND ADVANCING INNOVATIVE PRODUCT PIPELINE.INSYS THERAPEUTICS - ‍ALSO CONTINUE WORKING WITH AUTHORITIES TO RESOLVE ISSUES RELATED TO "INAPPROPRIATE ACTIONS" TAKEN BY FORMER EMPLOYEES​.INSYS THERAPEUTICS SAYS ‍LAST WEEK'S FEDERAL INDICTMENTS OF FIVE NEW YORK PHYSICIANS INVOLVE ALLEGATIONS RELATED TO FORMER EMPLOYEES​.INSYS THERAPEUTICS INC - STATEMENT AFTER ‍LAST WEEK'S FEDERAL INDICTMENTS OF FIVE NEW YORK PHYSICIANS INVOLVE ALLEGATIONS RELATED TO FORMER EMPLOYEES​.  Full Article

Neopharm to pay annual cash dividend as 500 won/share for 2017
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Neopharm Co Ltd <092730.KQ> ::Says it plans to pay annual cash dividend as 500 won/share to shareholders of record on Dec. 31, 2017.  Full Article

Insys Therapeutics Voting Trust Reports 58 Pct Stake In Insys As Of Feb 27
Friday, 9 Mar 2018 

March 8 (Reuters) - Insys Therapeutics Inc ::INSYS THERAPEUTICS INC VOTING TRUST REPORTS 58 PERCENT STAKE IN INSYS THERAPEUTICS AS OF FEB 27 - SEC FILING.INSYS THERAPEUTICS INC VOTING TRUST - NASDAQ AND U.S. DOJ REQUESTED THAT TRUST BE ENTERED INTO AND SHARES OWNED BY BENEFICIARIES BE PLACED INTO THE TRUST.INSYS THERAPEUTICS INC VOTING TRUST - TRUST IS IN ORDER TO LIMIT VOTING POWER OF DR. JOHN KAPOOR RELATED TO HIS OWNERSHIP STAKE IN COMPANY.  Full Article

Photo

Drugmaker Insys wins bankruptcy court approval to sell off opioid

Drugmaker Insys Therapeutics Inc on Thursday won court approval to sell its flagship fentanyl spray to a buyer who agreed to only market the drug for use by cancer patients, in response to concerns about the product's role in fueling the opioid epidemic.